The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?
The goal of this observational study is to clarify the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population aged from 18 to 75. The main question it aims to answer is: * What is the appropriate treatment strategy for patients diagnosed with tumor in sellar region with unruptured intracranial aneurysms? * Should the tumor be resected first followed by aneurysm treatment, or should the aneurysm be treated prior to tumor resection? Alternatively, is tumor resection alone with regular observation of the aneurysm a viable option? * What are the patient's intraoperative risks, postoperative complications, and prognosis? Participants are required to: * Provide detailed medical records. * Complete laboratory tests and imaging examinations at scheduled time points and cooperate with neurosurgeons for follow-up visits after the relevant treatments. This is an observational study. It solely collects patients' pre-operative, intra-operative, and post-operative follow-up information and does not influence the patient's treatment process or clinical decision-making.
Study Type
OBSERVATIONAL
Enrollment
608
Tumor resection followed by aneurysm treatment
Aneurysm treatment followed by tumor resection
Tumor resection without aneurysm treatment but observation
Beijing Tiantan Hospital affiliated to Capital Medical University
Beijing, China, China
Aneurysm progression
The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status
Time frame: From enrollment to the end of treatment at 24 months
Tumor related complication and progression
The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.
Time frame: From enrollment to the end of treatment at 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.